Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing`s Disease


A Randomized, Double-blind, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Pasireotide LAR in Patients With Cushing`s Disease




This is a randomized, double-blind, multicenter, phase III study to evaluate the safety and efficacy of 2 dosing regiments of Pasireotide long acting release (LAR) in patients with Cushing`s disease.

Study Status: Recruiting


Condition Intervention Phase
Cushing`s Disease Drug: SOM230 LAR 30 mg
Drug: SOM230 LAR 10 mg
Phase 3

Verified by Novartis Pharmaceuticals January, 2014

Sponsored by: Novartis Pharmaceuticals
Information provided by: Novartis identifier: NCT01374906

Study Type: Interventional

Study Design: Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Cleveland Clinic SC
Cleveland, Ohio 44195
United States

Novartis Pharmaceuticals., Study Director

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit
  Information obtained from on
Link to the current record.

Cleveland Clinic Mobile Site